Diamyd Medical Valuation
Is DMN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DMN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DMN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DMN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DMN?
Key metric: As DMN barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is DMN's PB Ratio? | |
|---|---|
| PB Ratio | 9.3x |
| Book | SEK 145.92m |
| Market Cap | SEK 1.35b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9374.6x |
| Enterprise Value/EBITDA | -8.3x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does DMN's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1.6x | ||
HPHA Heidelberg Pharma | 3.1x | -33.0% | €110.9m |
MDG1 Medigene | 0.9x | 11.0% | €17.0m |
2INV 2invest | 1x | n/a | €64.4m |
FYB Formycon | 1.5x | 32.4% | €882.8m |
DMN Diamyd Medical | 9.3x | -10.3% | €1.4b |
Price-To-Book vs Peers: DMN is expensive based on its Price-To-Book Ratio (9.3x) compared to the peer average (1.6x).
Price to Book Ratio vs Industry
How does DMN's PB Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Book vs Industry: DMN is expensive based on its Price-To-Book Ratio (9.3x) compared to the European Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is DMN's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 9.3x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate DMN's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Aspen Pharmacare Holdings
R73.7b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R8.60
7D
-3.9%
1Y
-0.6%
Collegium Pharmaceutical
US$990.4m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.00
7D
1.4%
1Y
25.0%
Pharming Group
€492.8m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.72
7D
-1.0%
1Y
-31.3%